MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

35.32 -0.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

34.96

Max

35.45

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+49.12% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	137M 5.7B
Iepriekšējā atvēršanas cena	35.43
Iepriekšējā slēgšanas cena	35.32

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. apr. 04:27 UTC

Galvenie ziņu notikumi

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

2026. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 18:30 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

2026. g. 3. apr. 18:14 UTC

Tirgus saruna

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

2026. g. 3. apr. 17:50 UTC

Tirgus saruna

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

2026. g. 3. apr. 17:44 UTC

Iegādes, apvienošanās, pārņemšana

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

2026. g. 3. apr. 16:50 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

2026. g. 3. apr. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 16:12 UTC

Peļņas

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. apr. 15:20 UTC

Galvenie ziņu notikumi

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

2026. g. 3. apr. 15:08 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

2026. g. 3. apr. 14:11 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

2026. g. 3. apr. 12:56 UTC

Tirgus saruna

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

2026. g. 3. apr. 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Meituan's Profitability Likely to Improve This Year -- Market Talk

2026. g. 3. apr. 07:45 UTC

Tirgus saruna

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. apr. 04:01 UTC

Tirgus saruna

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

2026. g. 3. apr. 02:01 UTC

Tirgus saruna

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

2026. g. 3. apr. 01:59 UTC

Tirgus saruna

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

2026. g. 3. apr. 01:44 UTC

Tirgus saruna

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

2026. g. 3. apr. 01:22 UTC

Tirgus saruna

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

49.12% augšup

Prognoze 12 mēnešiem

Vidējais 52.55 USD 49.12%

Augstākais 64 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.